VP, Market Development, Clinical Genomics & Bioinformatics, Qiagen Bioinformatics
Sean Scott is the VP and GM, Clinical Genomics for QIAGEN. Sean is responsible for QIAGEN’s Clinical Genomics product portfolio offering serving the needs of molecular diagnostics and molecular pathology testing laboratories related to NGS-based genetic test interpretation and reporting across germline and somatic test indications. Sean recently led the development of QIAGEN new Ingenuity Clinical Decision Support platform, an instrument platform, assay and pipeline agnostic solution, that enables clinical labs to scale annotation, interpretation and reporting of their screening, diagnostic and monitoring test offerings. Sean joined QIAGEN in 2013 through QIAGEN’s acquisition of Ingenuity Systems where he, prior to QIAGEN, spent six years as SVP, Global Commercial Operations and SVP, Corporate Development for Ingenuity Systems.
Integrating NGS-based Test Results with Clinical Outcomes Data to Improve Physician Decision Support
The integration of NGS-based Oncology diagnostics testing results with patients-like-me clinical outcomes data at the point-of-care to enable genomics guided clinical decision support remains a challenge for many healthcare providers. TransMed Systems and QIAGEN provide a case study on how this challenge can be overcome with fast time-to-value and low overall total-cost-ownership in small to mid-sized cancer centers.